Protein Triggers Advanced Prostate Cancer Recurrence

The new study may help solve the mystery of why does prostate cancer recur in men treated to get rid of circulating androgens such as testosterone. Furthermore, because chemotherapy after recurrence extends life by only a few months, this new research, "raises the exciting possibility that we can develop a specific drug against this,” said senior study co-author Dr. Young Whang, associate professor of medicine at University of North Carolina at Chapel Hill (UNC; NC, USA).

The protein, named Ack1, is a member of the tyrosine kinase gene family. Ack1 exerts its effect on the recurrence of the cancer by biochemically changing the now inactive androgen receptor in the nucleus of prostate of cells, according to a series of experiments conducted by lead author Dr. Nupam P. Mahajan, assistant professor of pharmacology, and other Lineberger scientists at the Lineberger Comprehensive Cancer Center at UNC. The kinase activates the receptor via phosphorylation--by adding a phosphate group to this protein molecule.

"This biochemical action converts a prostate cell that would need an androgen signal for its growth to one that is independent of the androgen signal,” said senior study co-author Dr. Shelton Earp, director of the Cancer Center, and professor of cancer research and professor of pharmacology and medicine.

Dr. Earp noted that until now, scientists have not completely understood what that conversion means. "Our experiments show that this heretofore understudied protein Ack1 may be crucial in at least a portion of these tumor recurrences. Nupam's study nails down the mechanism by which that conversion happens.”

Among the studies were those that involved mice that were unable to produce androgen. The animals were implanted with human prostate tumor cells containing an activated form of Ack1. "We found that when prostate tumor cells express activated Ack1, cancer grew aggressively in these mice,” Dr. Mahajan said. "This mimics what happens in patients undergoing hormone therapy.”

The researchers noted that approximately one-third of androgen-independent human prostate tumors contain an activated Ack1 molecule. "The study is telling us this is a target for therapy and perhaps a very important target for therapy,” Dr. Earp said.

The study was published May 15, 2007, in the Proceedings of the [U.S.] National Academy of Sciences.


Related Links:
University of North Carolina at Chapel Hill